MedTrace Logo

A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer

NCT00252161 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 316

Last updated 2016-09-22

No results posted yet for this study

Summary

The aim of this study is to evaluate survival benefit of TS-1 plus cisplatin as a neoadjuvant chemotherapy in gastric cancer patient with resectable type 4 (linitis plastica type) and large type 3 tumor in comparison with surgery alone.

Conditions

  • Gastric Neoplasm

Interventions

PROCEDURE

Gastrectomy with more than D2 dissection

Gastrectomy with more than D2 dissection

DRUG

Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy

Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Haruhiko Fukuda

    lead OTHER

Principal Investigators

  • Mitsuru Sasako, MD, PhD · Hyogo Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252161 on ClinicalTrials.gov